Mobile has revolutionised everyday life and now big pharma is using smartphones and other mobile devices to improve research and development.
Laura Manca
-
-
Posted: April 11, 2018Categories: Updates
A personalised vaccine which boosts a patient’s own immune system has nearly doubled the number of women surviving ovarian cancer by two years.
-
Posted: April 09, 2018Categories: Updates
Following an earlier negative decision, NICE is now recommending NHS use of Roche’s immunotherapy Tecentriq for lung cancer.
-
Posted: April 06, 2018Categories: Approvals
Rubraca (rucaparib), already approved as a treatment for BRCA positive ovarian cancer, has been approved as a maintenance therapy for ovarian cancer regardless of BRCA mutation.
-
The FDA approves Blincyto (blinatumomab) for patients with B-cell ALL, who are in remission but still have minimal residual disease.
-
Posted: March 22, 2018Categories: Approvals
FDA approves Tasigna (nilotinib) for certain pediatric patients with Ph+ CML in chronic phase.
-
Posted: March 21, 2018Categories: Approvals
FDA approves Genentech’s Lucentis (ranibizumab injection) syringe for diabetic macular edema and diabetic retinopathy.
-
CLL expert explains latest treatment developments in the field.
-
FDA expands approval of Adcetris (brentuximab vedotin) for first-line treatment of Stage III or IV classical Hodgkin lymphoma in combination with chemotherapy.
-
Posted: March 14, 2018Categories: Updates
Expert emphasises healthy lifestyle in prostate cancer care.
-
The FDA has approved a new HIV treatment for patients with limited treatment options.
-
Kymriah, the first FDA-approved CAR-T cell therapy, is showing promising results in treating children with acute lymphoblastic leukemia.